TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
Sekar, A.; Chatterjee, R.; Selvadurai, B. R.; Ray, L.; Verma, A.; Nataraj, N. B.; Garcia, D. D.; Giri, S.; Genna, A.; Karatekin, F.; Gupta, N.; Zerbib, M.; Vinik, Y.; Avioz, T.; Weizman, E.; David, E.; A. Schaffer, A.; Pan, Y.; Huang, H.; M van Weerden, W.; Corey, E.; Hunt, H.; Greenstein, A.; Blecher-Gonen, R.; Oren, R.; Afek, A.; Amit, I.; Lev, S.; Ku, A.; Kartal, S.; R. Bright, J.; T. Lis, R.; L. Dahut, W.; Sowalsky, A. G.; Ruppin, E.; Yarden, Y.
Show abstract
Approximately 50% of prostate cancer (PCa) patients harbor fusions involving the TMPRSS2 and ERG genes. Despite this, tailored therapies targeting the fused gene, tERG, remain undeveloped. Our study analyzed biopsy samples from two clinical trials assessing the efficacies of androgen receptor (AR) signaling inhibitors (ARSIs). The results revealed that tERG promotes resistance to ARSIs and is associated with elevated levels of the glucocorticoid receptor (GR). Subsequent assays showed that GR directly interacts with tERG, alleviates allosteric autoinhibition and prevents chemotherapy-induced tERG degradation. In PCa models, either inhibiting GR or lowering cortisol levels suppressed tumor growth in tERG-positive models, but not in fusion-negative models. In addition, patient-derived fusion-positive xenografts displayed enhanced sensitivity to combined GR and AR inhibitors. Collectively, these findings highlight TMPRSS2-ERG as a new biomarker and propose that simultaneous inhibition of GR and AR may specifically benefit tERG-positine patients. However, GR stimulatory corticosteroid therapies may not be advisable for this patient subgroup.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 97%
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 95%
- Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control 94%
Similar papers in this journal
- The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression 96%
- A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth 96%
- GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis 96%
Similar papers in this journal
- CRISPR/Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells 94%
- RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer 94%
- Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma 93%
Similar papers in this journal
- AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer 96%
- A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer 95%
- Androgen Receptor Signaling Regulates the Transcriptome of Prostate Cancer Cells by Modulating Global Alternative Splicing 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.